green liquid


Deloitte Legal advises Main Capital Partners on strategic partnership with biomedion

A Deloitte Legal team led by Felix Felleisen (Partner) and Max Lüerßen (Counsel; both Corporate/M&A, Düsseldorf) has advised strategic software investor Main Capital Partners on the acquisition of a substantial share in life and health sciences regulatory compliance software provider biomedion.

biomedion is a global provider of compliance management software for the life and health sciences industries with state-of-the-art solutions to support innovation throughout the life sciences lifecycle. With a broad product portfolio and technical expertise, biomedion's solutions meet the intelligent information and imaging needs of industry and academia. The company's products are based on state-of-the-art technologies, are innovative and scalable, and have won multiple awards.

Together with former key investors and managers, Main Capital Partners will support biomedion to further strengthen its existing market position and continue its strong growth trajectory by expanding into adjacent customer segments with high regulatory and data quality requirements. In addition to organic growth initiatives, selective add-on acquisitions also represent an important pillar of growth.

Felix Felleisen and Max Lüerßen have advised Main Capital Partners since the beginning of its expansion into Germany and have already accompanied the strategic software investor in a number of platform and add-on acquisitions. Most recently, the Deloitte Legal M&A lawyers had advised Main Capital Partners on, among other things, the following projects:

  • the sale of financial software provider b+m Group to German technology investor LEA Partners (nominated by The Private Equity Awards as DACH Deal Of The Year),
  • the acquisition of Swedish “spend analytics” specialists Spendency by Onventis, a Main portfolio company for digital source-to-pay solutions,
  • and finally the acquisition of software developer and service provider emagixx, which specializes in data quality management, by financial software provider FOCONIS, which is also part of the Main portfolio.

Main Capital Partners had recently announced that it had successfully completed the capital raising for two new funds, raising a total of more than 1.21 billion Euro. Following the launch of the new funds, the European software investor's assets under management have doubled to approximately 2.2 billion Euro. Main will use these funds to continue building strong European software groups in various market segments, pursuing both local buy-and-build strategies and cross-border growth strategies.

"Once again, we relied on the experience and expertise of Max Lüerßen and Felix Felleisen for this transaction," said Yves Souren (Senior Investment Manager Main Capital Partners DACH). "Their combination of collaborative approach, efficiency and pragmatism, as well as persistence in execution, make them ideally suited to work with our teams and our other advisors. Their commercial understanding allows them to accurately map complex issues, their orientation to our goals to master difficult negotiation situations."

Advisor Main Capital:
Deloitte Legal: Max Lüerßen (Counsel, Corporate/M&A, Düsseldorf, Lead), Felix Felleisen (Partner, Corporate/M&A, Düsseldorf, Co-Lead); Frauke Heudtlass (Partner, Employment Law, Düsseldorf); Dr. Fleur Johanna Prop, LL.M. (Counsel, Corporate/M&A, Düsseldorf), Pia Franziska Karapanos, LL.M. (Senior Associate, Corporate/M&A, Düsseldorf); Alexander Roehl, LL.M. (Associate, Corporate/M&A, Düsseldorf); Leonie Onkelbach (Associate, Employment Law, Düsseldorf)

Advisor to seller:

About biomedion-Group
Founded in 2000, biomedion develops the neuronOS platform, a modern software GxP data cloud platform in the life and health sciences industry to collect GLP raw data from instruments, archiving GxP information and ensuring compliance with regulatory provisions. Headquartered in Berlin with additional offices in Munich (Germany) and Phoenix (United States), biomedion serves worldwide leading top 20 pharmaceutical and biosimilar companies as well as their supporting Contract Research Organisations (CROs) and emerging biotech’s in Europe and North America.

About Main Capital
Main Capital Partners is a leading software investor in the Benelux, DACH and the Nordics. Main has almost 20 years of experience in strengthening software companies and works closely together with management teams of its portfolio companies as a strategic partner, in order to realise sustainable growth and build excellent software groups. Main counts over 45 employees and has offices in The Hague, Stockholm and Düsseldorf. As of October 2021, Main has over EUR 2.2 billion of assets under management. Main has invested in more than 120 software companies to date. These companies have created jobs for approximately 4,000 employees.

Did you find this useful?